Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
Add more filters








Publication year range
1.
Medicine (Baltimore) ; 103(22): e38383, 2024 May 31.
Article in English | MEDLINE | ID: mdl-39259089

ABSTRACT

BACKGROUND: Nonalcoholic steatohepatitis (NASH) is an important etiology of hepatocellular carcinoma (HCC), and there is no established therapy for this syndrome. Rapid-onset obesity with hypothalamic dysfunction, hypoventilation, autonomic dysregulation, and neural crest tumor (ROHHAD(NET)) is an extremely rare syndrome considered to be life-threatening, with death occurring around 10 years of age. We present the oldest known autopsy case of this syndrome that developed HCC. This case provided important information on not only improving the course of this syndrome, but also understanding the natural history and therapeutic modalities of NASH and HCC. METHODS: The patient was diagnosed with ROHHAD(NET) syndrome in childhood, and liver cirrhosis due to NASH was diagnosed at age 17. HCC was detected at age 20, and embolization and irradiation were performed. At age 21, she died from accidental acute pancreatitis and subsequent liver failure and pulmonary hemorrhage. RESULTS: Rapid onset of obesity, hypoventilation, and hypothalamic disturbance appeared in childhood and was diagnosed as this syndrome. At age 17, liver cirrhosis due to NASH was diagnosed by liver biopsy, and at age 20, HCC was diagnosed by imaging. Transarterial chemoembolization and irradiation were performed, and the HCC was well controlled for a year. CONCLUSION: At age 21, she died from accidental acute pancreatitis, subsequent liver failure and pulmonary hemorrhage. Autopsy revealed that the HCC was mostly necrotized. This case was valuable not only for other ROHHAD(NET) syndrome cases, but also in improving our understanding of the natural history of NASH and HCC.


Subject(s)
Autopsy , Carcinoma, Hepatocellular , Hypothalamic Diseases , Hypoventilation , Liver Neoplasms , Non-alcoholic Fatty Liver Disease , Humans , Female , Liver Neoplasms/pathology , Liver Neoplasms/complications , Liver Neoplasms/therapy , Carcinoma, Hepatocellular/pathology , Carcinoma, Hepatocellular/complications , Carcinoma, Hepatocellular/therapy , Hypoventilation/etiology , Hypoventilation/complications , Non-alcoholic Fatty Liver Disease/complications , Non-alcoholic Fatty Liver Disease/pathology , Hypothalamic Diseases/complications , Hypothalamic Diseases/diagnosis , Obesity/complications , Neuroendocrine Tumors/complications , Neuroendocrine Tumors/pathology , Neuroendocrine Tumors/therapy , Fatal Outcome , Young Adult , Autonomic Nervous System Diseases/etiology , Syndrome
2.
Clin J Gastroenterol ; 17(3): 505-510, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38587568

ABSTRACT

Hepatitis C virus (HCV) reactivation has been reported to be caused due to several anticancer drugs and immunosuppressive agents; however, HCV reactivation after steroid monotherapy has rarely been reported. Here, we report the case of a 65-year-old Japanese man with HCV infection who developed HCV reactivation after the administration of prednisolone (PSL) for 6 days for sudden deafness. In the patient history, the positivity for anti-HCV antibody was observed, but serum level of HCV RNA was not measured. Two months after PSL administration, the patient experienced an alanine aminotransferase (ALT) flare and the serum level of HCV RNA was observed to be 6.2 log IU/mL; then, the patient was admitted to our hospital for hepatitis treatment. Based on the clinical course and laboratory findings, the patient was diagnosed with HCV reactivation. Although the ALT levels decreased spontaneously during follow-up, they did not drop to normal range; subsequently, sofosbuvir and ledipasvir treatments were started. A sustained virological response 24 weeks after the end of treatment was achieved. This case study suggests that HCV reactivation with hepatitis flare can occur even after a steroid monotherapy, and doctors should pay attention to HCV reactivation when administering PSL for patients with HCV infection.


Subject(s)
Antiviral Agents , Hearing Loss, Sudden , Hepacivirus , Prednisolone , Virus Activation , Humans , Male , Aged , Prednisolone/therapeutic use , Hearing Loss, Sudden/drug therapy , Hearing Loss, Sudden/etiology , Hearing Loss, Sudden/virology , Virus Activation/drug effects , Antiviral Agents/therapeutic use , Hepacivirus/genetics , Hepatitis C/drug therapy , Hepatitis C/complications , Sofosbuvir/therapeutic use , Fluorenes/therapeutic use , Fluorenes/adverse effects , Benzimidazoles/therapeutic use , Benzimidazoles/adverse effects , Alanine Transaminase/blood , RNA, Viral/blood , Glucocorticoids/therapeutic use , Glucocorticoids/adverse effects
3.
J Gastroenterol ; 58(11): 1081-1093, 2023 Nov.
Article in English | MEDLINE | ID: mdl-37698719

ABSTRACT

Comprehensive genomic profiling based on next-generation sequencing has recently been used to provide precision medicine for various advanced cancers. Endoscopic ultrasound (EUS)-guided fine-needle aspiration (EUS-FNA) and EUS-guided fine-needle biopsy (EUS-FNB) play essential roles in the diagnosis of abdominal masses, mainly pancreatic cancers. In recent years, CGP analysis using EUS-FNA/FNB specimens for hepatobiliary-pancreatic cancers has increased; however, the success rate of CGP analysis is not clinically satisfactory, and many issues need to be resolved to improve the success rate of CGP analysis. In this article, we review the transition from EUS-FNA to FNB, compare each test, and discuss the current status and issues in genomic analysis of hepatobiliary-pancreatic cancers using EUS-FNA/FNB specimens.

4.
Nihon Shokakibyo Gakkai Zasshi ; 120(6): 500-507, 2023.
Article in Japanese | MEDLINE | ID: mdl-37302836

ABSTRACT

An 82-year-old female patient was admitted to our hospital for visual acuity loss in both eyes. The patient was diagnosed with invasive liver abscess syndrome and bilateral endophthalmitis due to Klebsiella pneumoniae 4 days after the onset of ocular symptoms. The liver abscess improved by broad-spectrum antibiotics and intravitreal injection, but bilateral blindness occurred. Most literature reported fever as the first symptom of invasive abscess syndrome, but this case had no fever at the onset of ocular symptoms. Delayed invasive liver abscess syndrome diagnosis might cause poor visual acuity prognosis.


Subject(s)
Endophthalmitis , Liver Abscess , Female , Humans , Aged, 80 and over , Klebsiella pneumoniae , Blindness , Endophthalmitis/drug therapy , Endophthalmitis/etiology , Liver Abscess/complications , Liver Abscess/diagnostic imaging
6.
Medicine (Baltimore) ; 101(35): e30486, 2022 Sep 02.
Article in English | MEDLINE | ID: mdl-36107543

ABSTRACT

RATIONALE: Hepatocellular carcinoma (HCC) is the sixth most common type of cancer globally. Since 2020, combination treatment with atezolizumab and bevacizumab were approved in patients with unresectable HCC in Japan, and atezolizumab plus bevacizumab is the first-line treatment for unresectable HCC. PATIENT CONCERNS: A 73-year-old Japanese man diagnosed with a large HCC was treated with atezolizumab plus bevacizumab. After 2 cycles, he had fever and fatigue and was admitted to the hospital. DIAGNOSIS: Abdominal contrast-enhanced computed tomography revealed tumor necrosis in HCC with gas formation in the necrotic area. Laboratory examination revealed a white blood cell (WBC) count of 16,340/µL and C-reactive protein (CRP) level of 33.0 mg/dL. Based on the above findings, he was diagnosed with a liver abscess. INTERVENTIONS: Percutaneous transhepatic liver abscess drainage and broad-spectrum antibiotics treatment were performed. OUTCOMES: Despite liver abscess drainage, persistent fever and no improvement in the WBC count or CRP level was observed. The patient's respiratory condition and renal function gradually worsened; The patient's general condition did not improve despite the ventilator support and continuous hemodiafiltration, and he died on day 37. LESSONS: We report the first case of liver abscess after atezolizumab plus bevacizumab treatment for unresectable HCC.


Subject(s)
Carcinoma, Hepatocellular , Liver Abscess , Liver Neoplasms , Aged , Anti-Bacterial Agents , Antibodies, Monoclonal, Humanized , Bevacizumab/therapeutic use , C-Reactive Protein , Carcinoma, Hepatocellular/complications , Carcinoma, Hepatocellular/drug therapy , Humans , Liver Abscess/diagnosis , Liver Abscess/drug therapy , Liver Abscess/etiology , Liver Neoplasms/therapy , Male
7.
Intern Med ; 61(10): 1503-1509, 2022 May 15.
Article in English | MEDLINE | ID: mdl-34744108

ABSTRACT

Panitumumab, a fully human anti-epidermal growth factor receptor (EGFR) monoclonal antibody, has been shown to be useful in treating either advanced or recurrent KRAS/NRAS/BRAF wild-type colorectal cancer. We herein report the case of a 60-year-old man with short bowel syndrome who developed hematochezia due to panitumumab-induced colitis with vitamin K deficiency during third-line chemotherapy. The cause of vitamin K deficiency was the lack of intravenous vitamin K supplementation following a change from central venous nutrition to peripheral venous nutrition. We advise clinicians to carefully check for colitis and manage the infusions of chemotherapy patients with short bowel syndrome.


Subject(s)
Antineoplastic Agents , Colitis , Colorectal Neoplasms , Short Bowel Syndrome , Vitamin K Deficiency , Antibodies, Monoclonal/adverse effects , Antineoplastic Agents/adverse effects , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Colitis/drug therapy , Colorectal Neoplasms/drug therapy , Gastrointestinal Hemorrhage/etiology , Humans , Male , Middle Aged , Mutation , Neoplasm Recurrence, Local/drug therapy , Panitumumab/adverse effects , Proto-Oncogene Proteins p21(ras)/metabolism , Short Bowel Syndrome/drug therapy , Vitamin K Deficiency/chemically induced , Vitamin K Deficiency/drug therapy
8.
Asian J Endosc Surg ; 15(1): 211-215, 2022 Jan.
Article in English | MEDLINE | ID: mdl-34342149

ABSTRACT

Pancreatic metastasis from renal cell carcinoma (RCC) is relatively rare. Surgical resection of the lesion is recommended if no residual tumor remains. Although there is no clear standard for surgical procedures, enucleation can be considered for small lesions. Lesion identification is important for enucleation, and contrast-enhanced ultrasound which takes advantage of the characteristics of hypervascular lesions was useful in a 68-year-old woman who underwent a left nephrectomy for RCC 11 years ago that was pathologically diagnosed as clear cell carcinoma. Recent computed tomography checkup showed a hypervascular tumor of 6 mm in the uncinated process and 10 mm in the pancreatic tail. Endoscopic ultrasonography-guided fine-needle aspiration was performed for the tail lesion, a diagnosis of clear cell carcinoma was made, and laparoscopic enucleation of the pancreatic tumors was performed aided by intraoperative contrast-enhanced ultrasound. The postoperative course was uneventful, and no pancreatic fistula occurred.


Subject(s)
Carcinoma, Renal Cell , Kidney Neoplasms , Laparoscopy , Pancreatic Neoplasms , Aged , Carcinoma, Renal Cell/diagnostic imaging , Carcinoma, Renal Cell/surgery , Endoscopic Ultrasound-Guided Fine Needle Aspiration , Female , Humans , Kidney Neoplasms/diagnostic imaging , Kidney Neoplasms/surgery , Pancreatic Neoplasms/diagnostic imaging , Pancreatic Neoplasms/surgery
9.
Nihon Shokakibyo Gakkai Zasshi ; 118(5): 480-489, 2021.
Article in Japanese | MEDLINE | ID: mdl-33967133

ABSTRACT

A 66-year-old man was admitted to our department with hypercalcemia, pancreatic and liver tumors, and periportal lymph node enlargement. Contrast-enhanced computed tomography revealed a tumor in the pancreatic tail and the right hepatic lobe along with periportal lymphadenopathy. Laboratory data revealed hypercalcemia and high serum parathyroid hormone-related protein (PTHrP) levels. Using a 22-gauge Franseen needle, we performed endoscopic ultrasonography-guided fine-needle biopsy of the pancreatic mass and an enlarged lymph node. Histopathological examination of the biopsy specimen revealed moderately to well-differentiated pancreatic adenocarcinoma with poorly differentiated squamous cell elements, as well as squamous cell carcinoma of the lymph node. Immunohistochemical examination showed that the pancreatic tissue was weakly immunopositive and the lymph node was strongly immunopositive for anti-PTHrP antibody. We diagnosed the patient with pancreatic adenosquamous carcinoma with liver and lymph node metastasis, associated with hypercalcemia of malignancy secondary to PTHrP secretion. We administered systemic chemotherapy comprising gemcitabine and nab-paclitaxel. Unfortunately, the patient died 8 months after being diagnosed with this malignancy. PTHrP-producing adenosquamous carcinoma of the pancreas is rare;only 14 cases are reported in the literature. Based on immunohistochemical evaluation, this case report suggests that metastatic lymph nodes may lead to the overproduction of PTHrP in such cases.


Subject(s)
Adenocarcinoma , Pancreatic Neoplasms , Aged , Biopsy, Fine-Needle , Humans , Male , Pancreatic Neoplasms/diagnostic imaging , Parathyroid Hormone-Related Protein , Ultrasonography, Interventional
10.
Intern Med ; 60(17): 2783-2791, 2021 Sep 01.
Article in English | MEDLINE | ID: mdl-33746162

ABSTRACT

Although cases of gastrointestinal toxicity of pembrolizumab have been reported, cases of acute immune-mediated colitis accompanied with metachronous esophageal disorders (esophagitis and ulcer) are rare. We herein report a case of acute colitis and metachronous esophageal ulcers due to an immune-related adverse event following concomitant pembrolizumab chemotherapy for lung adenocarcinoma. To our knowledge, there have so far been no reports of cases in which both acute immune-mediated colitis and metachronous esophageal ulcers developed. We therefore report the details of this case along with a review of the pertinent literature.


Subject(s)
Colitis , Esophageal Diseases , Esophagitis , Colitis/chemically induced , Colitis/diagnosis , Esophageal Diseases/chemically induced , Esophageal Diseases/diagnosis , Humans , Immune Checkpoint Inhibitors , Ulcer/chemically induced , Ulcer/diagnosis
SELECTION OF CITATIONS
SEARCH DETAIL